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Abstract
Introduction: Critically ill patients are characterized as individuals hospitalized in the Intensive Care Unit (ICU) and
can evolve to sepsis, septic shock or even death. Among others, genetic factors can influence the outcome of
critically ill patients. HLA-G is a non-classical class Ib molecule that has limited protein variability, presenting seven
isoforms generated by alternative splicing, and presents immunomodulatory properties. Polymorphisms at the
3’UTR are thought to influence HLA-G gene expression. It was previously observed that increased sHLA-G5 levels
were predictive of survival among septic shock patients. We assessed the frequencies of 7 polymorphisms in exon
8 at the 3’ UTR of HLA-G and associated these variants with different clinical outcomes in critically ill patients.
Methods: Exon 8 at the 3’ UTR of the HLA-G gene from 638 critically ill subjects was amplified by PCR and
sequenced. Genotypes were identified using FinchTV software v.1.4.0 and the most probable haplotype
constitution of each sample was determined by PHASE software v.2.1. Haplotype frequencies, linkage
disequilibrium, heterozygosity test and Hardy-Weinberg Equilibrium were estimated using ARLEQUIN software v.3.5.
Results: Among all critically ill patients, an association between carriers of the +2960IN_+3142 G_+3187A
haplotype and septic shock (P = 0.047) was observed. Septic patients who carried the +2960IN_+3142G_+3187A
haplotype presented an increased risk for septic shock (P = 0.031).
Conclusions: The present study showed, for the first time, an association between polymorphisms in exon 8 at the
3 ‘UTR of HLA-G gene and outcomes of critically ill patients. These results may be important for understanding the
mechanisms involved in evolution to septic shock in critically ill patients.
Introduction
Critically ill patients are individuals hospitalized in the
ICU, who can evolve to sepsis, septic shock, death, or
survival [1]. Massive resources have been invested in
sepsis control, either in public or private sectors, and
sepsis is the major cause of death in Brazilian ICUs
according to ILAS (Instituto Latino Americano de
Sepse) [2]. Several factors influence the outcome of criti-
cally ill patients, including different degrees of inflam-
matory response to infections and genetic factors [3].
Human leucocyte antigen G (HLA-G) is a non-classical
class Ib molecule that differs from classical class I
molecules mainly due to limited protein variability,
expression of seven isoforms (HLA-G1-4 membrane-
bound forms and HLA-G5-7 soluble forms) generated
by alternative splicing [4], and by its immunomodulatory
properties [5]. HLA-G molecules, through binding to
specific receptors (ILT-2 (LILRB1 and CD85j)) [6], (LT-
4 (LILRB2 and CD85d)) [7] and KIR2DL4 (CD158d) [8])
can inhibit the cytotoxic activity, and mediate apoptosis
of CD8+ T cells and natural killer (NK) cells, the prolif-
erative response of CD4+ T cells, and target them for
an immunosuppressive profile and the differentiation of
antigen-presenting cells and B cells [9], as well as being
involved in Th1/Th2 balance [10,11].
In non-pathological conditions, HLA-G expression is
highly tissue-specific and can be detected in trophoblast
cells, medullary cells of the thymus, cornea, pancreatic
islets and adult endothelial cell precursors [12]. The
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HLA-G molecule has been implicated in several condi-
tions, such as pregnancy [13-15], acceptance of allografts
[16-18], evasion of tumors [19-24] or viral infections
[25-32] from immune response, inflammatory autoim-
mune diseases [33-47], and spontaneous intracerebral
hemorrhage [48]. So far, only one study has investigated
HLA-G expression in critically ill patients with septic
shock, observing that increased HLA-G5 levels were
predictive of survival among these patients [49].
The HLA-G gene is located in the HLA complex at
the 6p21.3 chromosome region [50,51]. HLA-G gene
expression is regulated by several factors which are not
yet completely elucidated, and both its long promoter
region, and its 3’ untranslated region (UTR) are sup-
posed to play important roles in this process. Of note,
the 3’ UTR contains eight polymorphisms, most of
which are localized at putative miRNA binding sites
[52,53], and three of them were previously associated
with differential expression levels of HLA-G: a 14 bp
insertion/deletion at position +2960 (rs1704), which is
also associated with alternative splicing [54]; a C/G SNP
at +3142 (rs1063320), which is located within an
miRNA target site and has been shown to differentially
affect miRNA binding [52,53,55]; and an A/G SNP at
+3187 (rs9380142) that is found 4-bp upstream, an
AUUUA motif which has been recognized as an (AU)-
rich motif sequence that mediates mRNA degradation
[56]. The 14 bp insertion has been repeatedly associated
with lower levels of the molecule in different studies
[37,57-60]. It is noteworthy that this variant is almost
always accompanied by +3142G and +3187A alleles,
both previously associated with low mRNA availability,
indicating that the lower mRNA production associated
with 14-bp insertion might be a consequence of the
combined presence of these polymorphisms [61].
In the present study, we assessed the frequencies of
the haplotype composed by the 14 bp insertion, the
+3142G and the +3187G SNPs and, additionally, the
allelic and genotypic of the above-mentioned poly-
morphisms and four other 3’UTR HLA-G SNPs:
+3003C>T (rs1707), +3010C>G (rs1710), +3027A>C
(rs17179101) and +3035C>T (rs17179108), and sought
to associate these variants with different clinical out-
comes in critically ill patients.
Materials and methods
Patients
Blood samples were obtained from 638 ICU patients
from Hospital São Lucas of Pontifícia Universidade
Católica do Rio Grande do Sul (PUCRS), located in
Porto Alegre, Rio Grande do Sul, the southernmost
state of Brazil, between 2004 and 2010. Definition of
sepsis and septic shock followed the American College
of Chest Physicians/Society of Critical Care Medicine
Consensus Conference Committee criteria [62]. Sepsis is
defined as the occurrence of systemic inflammatory
response syndrome (SIRS) caused by the presence of
infection or clinical evidence of infection. SIRS is mani-
fested by two or more of the following symptoms: fever
(temperature > 38.0°C) or hypothermia (temperature <
35.5°C), tachycardia (> 90 beats/minute), tachypnea (> 20
breaths/minute), leukocytosis or leukopenia (white blood
cell count > 12.000 or < 4.000 cells/µl). Septic shock is
defined as the presence of SIRS, documented infection or
positive blood culture or organ dysfunction, hypoperfu-
sion abnormality or hypotension. The definition of hypo-
tension is systolic blood pressure < 90 mm Hg or a
reduction in systolic blood pressure of 40 mm Hg.
The following exclusion criteria were applied for this
study: 1 HIV-positive patients, 2) pregnancy, and 3)
patients receiving immunosuppressive therapy. Also,
patients readmitted to ICU from whom data were pre-
viously collected were excluded. Social and demographic
data (age, sex, length of stay in ICU and in hospital) and
clinical data (dysfunction and failure of six organ sys-
tems during the first week of ICU admission (Sequential
Organ Failure Assessment, SOFA score), and physiologi-
cal variables on the day of ICU admission (Acute Phy-
siology and Chronic Health Evaluation, APACHE II
score) were obtained from all patients, in addition to the
occurrence of sepsis, septic shock and death.
The protocol of the study was approved by the
PUCRS Ethics Committee (CEP-11/05593) and all
patients or their surrogates gave written informed con-
sent before blood withdrawal.
3’ UTR polymorphisms evaluation
Genomic DNA was extracted according to Lahiri and
Nurnberger (1991) [63]. Exon 8 at the 3’ UTR of the
HLA-G gene of each sample was amplified by PCR (pri-
mers HLA-G8F: 5’ TGTGAAACAGCTGCCCTGTGT3’
and HLA-G8R: 5’GTCTTCCATTTATTTTGTCTCT 3’)
[61]. Amplification was performed in a final volume of
25 µl containing 0.2 mM each of dNTP; 1.5 mM MgCl2;
10 pmol/µl of each primer; 1 unit of Taq Platinum High
Fidelity in 1X PCR-specific buffer (Invitrogen-Life Tech-
nologies, São Paulo, Brazil) and 10 to 100 ng of genomic
DNA. The initial denaturation cycle was carried out at
94ºC for 5 minutes; followed by 35 cycles at 95ºC for 45
s; 56ºC for 45 s; 72ºC for 1 minute and by a final exten-
sion step at 72ºC for 7 minutes. The amplification pro-
duct was quantified (10 to 50 ng/µl) by Low Mass
(Invitogen-Life Technologies, São Paulo, Brazil) in 1%
agarose gel. Fragments with 14 bp insertion presented
361 pb. PCR products were directly sequenced using the
primer HLA-G8R: 5’GTCTTCCATTTATTTTGTCTCT
3’ in an ABI 3730 XL DNA Sequencer according to the
manufacturer’s manual. Genotyping was performed by
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interpretation of chromatogram peaks by sequencing
FinchTV software version 1.4.0.
The PHASE software version 2.1 [64,65] was used to
determinate the most probable haplotype constitution of
each sample. Six independent runs with different seed
values provided the same results by PHASE methods.
The lowest probability value was between 0.9650 and
1.0000. Haplotype frequencies, linkage disequilibrium
(LD), heterozygosity test and Hardy-Weinberg Equili-
brium (HWE) were defined using ARLEQUIN software
version 3.5 [66].
Statistical analysis
Statistical calculations were performed using statistical
package SPSS 18 (SPSS 18.0 for Windows, Chicago, Illi-
nois, USA). Unless otherwise stated, continuous variable
results were expressed as mean ± SD, and categorical
variables as frequencies and percents. For the categorical
data we used Pearson chi square test. The Bonferroni
correction was applied when P values were significant.
All reported P-values are two-tailed and considered sta-
tistically significant when 0.05 or less.
Results and discussion
The median age among the 638 critically ill patients
(53.0% male and 47.0% female) was 57 years (13min/
97max). Of the 638 patients, 73.5% (n = 469) developed
sepsis, 51.6% (n = 329) progressed to septic shock,
32.9% (n = 210) died in the ICU; the mortality rate in
the ICU + hospital was 45.7% (n = 290). Other clinical
details are displayed in Table 1.
Allelic, genotype, haplotype and diplotype frequencies
Table 2 presents allelic and genotypic frequencies of
polymorphisms in critically ill patients. These frequen-
cies are in agreement with other studies in Brazilian
populations with a similar ethnic background [67,68].
Therefore, our sample is representative of the popula-
tion of southern Brazil, which has a major contribution
from European ancestry [68,69].
The heterozygosity test indicated an observed hetero-
zygosity higher than expected at the +2960INDEL,
+3010C>G, +3142C>G and +3187A>G polymorphisms
(Table 3). These polymorphisms were not in HWE. Cas-
telli et al. (2011) also reported disagreement on HWE
for +2960INDEL polymorphism in a Brazilian popula-
tion. It is interesting that the diversity of the HLA-G
locus is eight times higher than the average of the diver-
sity of the human genome [55]. Moreover, among the
HLA-G regions, the 3’ UTR region shows more diversity
than the promoter and the 5’ upstream regulatory
regions (5’URR) [67].
A strong LD was observed between all polymorphic
sites (P < 0.01, data not shown), which is consistent with
data available in the literature [61]. According to the
PHASE software, there were 22 different inferred haplo-
types among critically ill patients. The most frequent
haplotypes were UTR-1 (27.90%), UTR-2 (26.65%), UTR-
Table 1 Clinical and demographic data of critically ill
patients
Variables Values in critically ill patients (n
= 683)
Age, years 57 (13/97)
Male, n (%) 338 (53.0)
APACHE II score, mean (SD) 19.32 (7.73)










Length of stay, days, median
(min/max)
ICU 13 (0/173)
ICU + hospital 35 (1/242)
With sepsis, n (%) 469 (73.5)
With septic shock, n (%) 329 (51.6)
ICU mortality, n (%) 210 (32.9)
ICU + hospital mortality, n (%) 290 (45.7)
APACHE-II: Acute Physiology and Chronic Health Evaluation II; SOFA:
Sequential Organ Failure Assessment; n: number of patients.
Table 2 HLA-G 3’UTR allelic and genotypic frequencies among critically ill patients
+2960 INDEL +3003C>T +3010C>G +3027A>C +3035C>T +3142C>G +3187A>C
Allelic DEL 0.578 C 0.109 C 0.521 A 0.034 C 0.861 C 0.463 A 0.699
IN 0.421 T 0.890 G 0.478 C 0.965 T 0.141 G 0.536 C 0.304
Genotypic DEL/DEL 0.310 C/C 0.013 C/C 0.251 A/A 0.001 C/C 0.734 C/C 0.180 A/A 0.448
DEL/IN 0.536 C/T 0.194 C/G 0.541 A/C 0.066 C/T 0.255 C/G 0.566 A/C 0.503
IN/IN 0.154 T/T 0.793 G/G 0.208 C/C 0.933 T/T 0.011 G/G 0.254 C/C 0.049
P HWE >0.05 <0.05 >0.05 <0.05 <0.05 >0.05 >0.05
HWE: Hardy-Weinberg equilibrium.
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3 (10.42%), UTR-5 (10.03%) and UTR-4 (8.93%) (haplo-
type nomenclature according to [61]). The two most fre-
quent haplotypes observed among critically ill patients
were also the most frequent in populational studies with
southern Brazilian healthy populations [61,67,68]. Also,
we observed 64 different diplotypes, with the
DTGCCCG/ITCCCGA (UTR-1/UTR-2) diplotype being
the most frequent among critically ill patients (15.8%).
Assuming that the Brazilian population is a heteroge-
neous one [67], this diversity was expected due to its
colonization history [68,69]. Furthermore, it has already
been suggested, and our data also support this view, that
this region is under balancing selection, in which there is
a selection of heterozygotes [55,67]. The selection of het-
erozygote could be evolutionarily advantageous, since it
could promote a balance between high and low HLA-G
expression, according to the biological context.
Polymorphic variants of HLA-G and outcomes of critically
ill patients
Possible outcomes considered were sepsis, septic shock,
ICU mortality and ICU+hospital mortality among
patients with septic shock. The genotypes of each SNP
were tested separately for progression to sepsis, septic
shock, death in the ICU and death in the ICU + hospi-
tal; however no significant differences were observed.
Haplotype and diplotype frequencies, when subjected to
the same tests, were not associated with the considered
outcomes (data not shown).
From all analyzed variants, +2960IN, +3142G and
+3187A alleles had already been associated with reduced
HLA-G expression [57,61]. Considering a potential
interaction effect and the strong LD observed for these
three variants, haplotypes encompassing those variants
were determined and the presence/absence of this parti-
cular haplotype (+2960IN_+3142G_+3187A) was ana-
lyzed in relation to the studied clinical outcomes.
As can be observed in Table 4, among all critically ill
patients, carriers of the +2960IN_+3142G_+3187A haplo-
type were more likely to develop septic shock (P = 0.047).
When considering only patients who developed sepsis,
carriers of this haplotype were more likely to develop sep-
tic shock (odds ratio, OR = 1.62, 95% CI 1.04, 2.50, P =
0.031) (Table 5). When analyzing mortality among
patients with septic shock, no significant differences were
observed (Table 5).
Next, we sought to investigate if specific clinical out-
comes could be associated with a particular polymorph-
ism among critically ill patients. For each polymorphism,











*Polymorphisms with observed heterozygosity values greater than expected.
Table 4 Carriers and noncarriers of the +2960IN_+3142G_+3187A haplotype and clinical features among 683 critically
ill patients
Variables Number (%) of carriers of +2960IN_+3142G_
+3187A




Frequency 436 (68.3) 202 (31.7) -
With sepsis 323 (74.1) 146 (72.3) 0.701
With septic shock 237 (54.4) 92 (45.5) 0.047*
ICU mortality 149 (34.2) 61 (30.2) 0.366
ICU + hospital
mortality
201 (46.1) 89 (44.1) 0.692
P-value, Pearson chi-Square test with the Yates correction; *comparison between carriers and noncarriers of the haplotype +2960IN_+3142G_+3187A.
Table 5 Presence/absence of the +2960IN_+3142G_+3187A (IN-G-A) haplotype in relation to progression to septic
shock (SS) and mortality after SS among patients with sepsis
With IN-G-An (%) Without IN-G-An (%) Odds ratio(95% CI) P-value
With sepsis 323 (68.9) 146 (31.1) -
Progression to SS 237 (73.4) 92 (63.0) 1.62 (1.04-2.50) 0.031*
Without SS 86 (26.6) 54 (37.0)
ICU mortality (among SS patients) 122/237 (51.5) 48/92 (52.2) 0.97 (0.58-1.62) 0.990
ICU + hospital mortality (among SS patients) 149/237 (62.9) 61/92 (66.3) 0.86 (0.50-1.47) 0.649
P-value, Pearson chi-Square test with the Yates correction; *chi-square test significant (P < 0.05).
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individuals were grouped according to presence/absence
of a given allele and tested for association between a par-
ticular allele carrier and outcomes (progression to sepsis,
septic shock, ICU mortality and ICU+hospital mortality).
Among all critically ill patients there were no significant
differences for sepsis (Table 6).
Among patients who developed sepsis, +2960IN allele
carriers presented a higher frequency among patients
who progressed to septic shock (P = 0.046), although
this finding was not statistically significant after Bonfer-
roni correction for multiple comparisons (Table 7).
Among patients who developed septic shock, no signifi-
cant differences in mortality rate were associated with
presence/absence of a given allele (Table 7).
The present study observed an association between
haplotypes in exon 8 at 3’ UTR of the HLA-G gene and
outcomes in critically ill patients. These results may be
important for understanding the mechanisms involved
on evolution to septic shock in critically ill patients. So
far, there has only been one study of HLA-G in critically
ill patients, in which a higher concentration of soluble
HLA-G5 was observed, and was predictive of survival
after progression to septic shock [49]. Our results sug-
gest that critically ill patients who are carriers of
+2960IN_+3142G_+3187A haplotype, associated with a
reduced HLA-G expression, are more likely to develop
septic shock. Therefore, our results reinforce the idea
that decreased production of HLA-G in ICU patients
could have a negative impact on patient outcome.
Conclusions
The present study shows for the first time an association
between the +2960IN_3142G_3187A haplotype and sep-
tic shock among critically ill patients. Given the immu-
nomodulatory properties of HLA-G, we can propose an
important role for HLA-G in the mechanisms that
define outcomes in critically ill patients.
Opportunely, it should be interesting to analyze other
parameters to confirm this association, such as Il-10 and
glucocorticoids levels, and cytokine profile in critically
Table 6 Presence/absence of each allele of a given polymorphism and sepsis in all critically ill patients
Polymorphism Outcome With IN, n (%) Without IN, n (%) P-value
+ 2960INDEL Total of ICU patients 440 (69.0) 198 (31.0) -
With sepsis 326 (74.1) 143 (72.2) 0.691
Without sepsis 114 (25.9) 55 (27.7)
Polymorphism Outcome With +3003C, n (%) Without +3003C n, (%) P-value
+3003C>T Total of ICU patients 132 (20.7) 506 (79.3) -
With sepsis 98 (74.2) 371 (73.3) 0.831
Without sepsis 34 (25.8) 135 (26.7)
Polymorphism Outcome With +3010C n, (%) Without +3010C, n (%) P-value
+3010C>G Total of ICU patients 505 (79.2) 133 (20.8) -
With sepsis 373 (73.9) 96 (72.2) 0.699
Without sepsis 132 (26.1) 37 (27.8)
Polymorphism Outcome With +3027A, n (%) Without +3027A, n (%) P-value
+3027A>C Total of ICU patients 43 (6.7) 595 (93.3) -
With sepsis 36 (83.7) 433 (72.8) 0.116
Without sepsis 7 (16.3) 162 (27.2)
Polymorphism Outcome With +3035T, n (%) Without +3035T, n (%) P-value
+3035C>T Total of ICU patients 170 (26.6) 468 (73.4) -
With sepsis 125 (73.5) 344 (73.5) 0.995
Without sepsis 45 (26.5) 124 (26.5)
Polymorphism Outcome With +3142G, n (%) Without +3142G, n (%) P-value
+3142C>G Total of ICU patients 523 (82.0) 115 (18.0) -
With sepsis 391 (75.0) 78 (67.8) 0.159
Without sepsis 132 (25.0) 37 (32.2)
Polymorphism Outcome With +3187A, n (%) Without +3187A, n (%) P-value
+3187A>G Total of ICU patients 607 (95.1) 31 (4.9) -
With sepsis 447 (73.6) 22 (71.0) 0.742
Without sepsis 160 (26.4) 9 (29.0)
P-value, chi square test; *low values of P.
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ill patients. All these results will provide insights into
the understanding of critical illness.
Key message
• Critically ill patients and critically ill patients who evolve
to sepsis carriers of the +2960IN_+3142G_+3187A haplo-
type, are more likely to develop septic shock.
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